home / stock / inm / inm news


INM News and Press, InMed Pharmaceuticals Inc. From 12/20/23

Stock Information

Company Name: InMed Pharmaceuticals Inc.
Stock Symbol: INM
Market: NASDAQ
Website: inmedpharma.com

Menu

INM INM Quote INM Short INM News INM Articles INM Message Board
Get INM Alerts

News, Short Squeeze, Breakout and More Instantly...

INM - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Approves Election of Directors During 2023 Annual General Meeting

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2023 annual general meeting. According to the report, during the meeting, which was held...

INM - InMed Announces Results of 2023 Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed " or the " Company "), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual g...

INM - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular Degeneration

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced the launch of INM-089, a cannabinol (“CBN”) analog, to investigate its effects in the treatme...

INM - InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

INM-089 improves retinal function in in vivo preclinical AMD disease model Establishes cannabinol (CBN) analog candidate in a new disease target Vancouver, British Columbia--(Newsfile Corp. - November 29, 2023) - InMed Pharmaceuticals Inc. ( NASDAQ: INM ) (" InMed " or the " Company "), a le...

INM - InMed Pharmaceuticals GAAP EPS of -$0.76, revenue of $901.8M

2023-11-14 09:44:03 ET More on InMed Pharmaceuticals InMed Pharmaceuticals to raise $5.2M via private placement Historical earnings data for InMed Pharmaceuticals Financial information for InMed Pharmaceuticals For further details see: InMed Pharmaceutica...

INM - InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today reports f...

INM - Expected US Company Earnings on Friday, November 10th, 2023

Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...

INM - InMed Pharmaceuticals files to sell 12.57M shares for holders

2023-11-08 17:55:47 ET More on InMed Pharmaceuticals InMed Pharmaceuticals to raise $5.2M via private placement Historical earnings data for InMed Pharmaceuticals Financial information for InMed Pharmaceuticals For further details see: InMed Pharmaceutica...

INM - InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled fo...

INM - InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Vancouver, British Columbia--(Newsfile Corp. - November 2, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed " or the " Company "), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that ...

Previous 10 Next 10